BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BerGenBio ASA (BGBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014121
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BerGenBio ASA (BerGenBio) is a developer of drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 finds application in the treatment of drug resistant chronic myeloid leukemia. BerGenBio’s cellselect is a drug discovery and validation technology that identifies and validates novel drug targets and biomarkers. The company’s cellselect imaging allows cell sorting, selection and in-vivo disease imaging. Its cellselect modelling and regulated translational tools are used in treating in-vivo modeling. BerGenBio is headquartered in Bergen, Norway.

BerGenBio ASA (BGBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BerGenBio ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Secures US$1.3 Million In Venture Financing 14
Partnerships 15
BerGenBio Enters into Agreement with Merck 15
Licensing Agreements 16
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 16
Equity Offering 18
BerGenBio Raises USD47 Million in IPO 18
BerGenBio Raises USD25 Million in Private Placement of Shares 19
BerGenBio Raises USD12 Million in Private Placement of Shares 20
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 21
BerGenBio ASA – Key Competitors 22
BerGenBio ASA – Key Employees 23
BerGenBio ASA – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 18, 2017: BerGenBio: Results for the Second Quarter and Half year 2017 25
May 23, 2017: BerGenBio: Results for the First Quarter 2017 26
Product News 28
11/29/2016: BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium 28
06/06/2017: BerGenBio’s selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 29
04/12/2016: Rigel Announces Presentation on preclinical research project MerTK at Upcoming American Association of Cancer Research (AACR) Conference 30
01/09/2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017 31
Clinical Trials 32
May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 32
Dec 08, 2016: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance 33
Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016 34
Sep 25, 2016: New BGB324 study points to novel mechanism to enhance immunotherapy efficacy 35
Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 36
Apr 18, 2016: BerGenBio presents new data demonstrating that BGB324 enhances checkpoint inhibitor blockade 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
BerGenBio ASA, Pharmaceuticals & Healthcare, Key Facts 2
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BerGenBio ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BerGenBio ASA, Deals By Therapy Area, 2011 to YTD 2017 9
BerGenBio ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
BerGenBio Raises US$6.4 Million In Venture Financing 11
BerGenBio Secures US$8.8 Million In Series A Financing 13
BerGenBio Secures US$1.3 Million In Venture Financing 14
BerGenBio Enters into Agreement with Merck 15
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 16
BerGenBio Raises USD47 Million in IPO 18
BerGenBio Raises USD25 Million in Private Placement of Shares 19
BerGenBio Raises USD12 Million in Private Placement of Shares 20
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 21
BerGenBio ASA, Key Competitors 22
BerGenBio ASA, Key Employees 23

★海外企業調査レポート[BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SMART Medical Systems Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Smart Medical Systems Ltd (Smart) is a medical device company that develops and manufactures gastroenterology and GI endoscopy devices. The company offers products such as inflation systems, platform, naviaid ABC, G-eye, naviaid AB, future naviaid products, controlled withdrawal, and others. …
  • SPI Energy Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Spi Energy Co Ltd (Spi Energy), formerly Solar Power Inc, is a photovoltaic (PV) solutions provider. The company offers development, financing, installation, operation and sale of utility-scale and residential solar power projects. It also operates online energy e-commerce and investment pla …
  • LinkedIn Corp:企業の戦略的SWOT分析
    LinkedIn Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Copperbelt Energy Corporation Plc (CEC):企業の財務・戦略的SWOT分析
    Copperbelt Energy Corporation Plc (CEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Trustpower Limited (TPW)-エネルギー分野:企業M&A・提携分析
    Summary TrustPower Limited (Trustpower) is an energy utility that retails electricity, gas and telecommunication services. The company produces electricity from wind, hydro, and diesel sources. It owns and operates various power projects across New Zealand and Australia. Trustpower also leases elect …
  • Cytokinetics Inc (CYTK)-製薬・医療分野:企業M&A・提携分析
    Summary Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases, which compromise muscle performance. The company’s lead drug candidate, tirasemtiv, a fast skeletal muscle troponin activa …
  • ScinoPharm Taiwan Ltd (1789):製薬・医療:M&Aディール及び事業提携情報
    Summary ScinoPharm Taiwan Ltd (ScinoPharm) provides process research and development (R&D) and active pharmaceutical ingredient (API) manufacturing services to the pharmaceutical industry. It services include custom synthesis for early phase pharmaceutical activities, brand companies and APIs for th …
  • Telekom Malaysia Berhad (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Berhad (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Reliance Industries Ltd (RELIANCE):石油・ガス:M&Aディール及び事業提携情報
    Summary Reliance Industries Ltd (RIL) is a conglomerate with business interests in energy, petrochemicals, textiles, retail, and telecommunication sectors. The company carries out exploration, development and production of oil and gas, refining of crude oil, marketing of petroleum products, and prod …
  • Corona Remedies Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Corona Remedies Pvt Ltd (Corona) is a drugs manufacturing company that develops, manufactures, and markets pharmaceutical products. The company’s products include antiallergic drugs, antibiotic drugs, analgesic drugs, antimalarial drugs, heamatonics, hormonal drugs, nutritional supplements, …
  • Finley Resources Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Finley Resources Inc (Finley) is an oil and gas company that owns, manages, operates and develops oil and gas properties. The company operates its oil and gas properties in the areas of Permian Basin, South Texas, East Texas, Mississippi, Barnett Shale, San Juan Basin, Alabama, Oklahoma and …
  • Genuine Parts Company:企業の戦略・SWOT・財務情報
    Genuine Parts Company - Strategy, SWOT and Corporate Finance Report Summary Genuine Parts Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hasbro Inc (HAS):企業の財務・戦略的SWOT分析
    Hasbro Inc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Immatics Biotechnologies GmbH:企業の戦略的SWOT分析
    Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • New China Life Insurance Company Ltd.:企業の戦略・SWOT・財務分析
    New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Poupart Limited:企業の戦略・SWOT・財務分析
    Poupart Limited - Strategy, SWOT and Corporate Finance Report Summary Poupart Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Medpace Inc (MEDP):企業の財務・戦略的SWOT分析
    Summary Medpace Inc (Medpace), a subsidiary of Medpace Holdings Inc is a contract research organization that develops research based drug and medical device. The organization provides services such as medical affairs, regulatory affairs and medical writing, clinical monitoring, clinical trial manage …
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • McWane Inc:企業の戦略的SWOT分析
    McWane Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Medusa Mining Ltd:企業の戦略・SWOT・財務情報
    Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆